Cancer Res Treat.  2021 Oct;53(4):1113-1122. 10.4143/crt.2020.817.

Fasting Blood Glucose, Cholesterol, and Risk of Primary Liver Cancer: The Kailuan Study

Affiliations
  • 1Department of Hepatobiliary Surgery, Kailuan General Hospital, Tangshan, China
  • 2Graduate School of North China University of Science and Technology, Tangshan, China

Abstract

Purpose
The influence of fasting blood glucose (FBG) and cholesterolemia primary liver cancer (PLC) in china was analyzed via a large prospective cohort study based on a community population, and the combined effects between them were investigated.
Materials and Methods
Overall, 98,936 staff from the Kailuan Group who participated in and finished physical examinations between 2006 and 2007 were included in the cohort study. Their medical information was collected and they were followed up after examination. The correlations of serum FBG or TC with PLC were analyzed. Then, we categorized all staff into four groups: normal FBG/ non-hypocholesterolemia, normal FBG/hypocholesterolemia, elevated FBG/non-hypocholesterolemia, elevated FBG/hypocholesterolemia and normal FBG/ non-hypocholesterolemia was used as a control group. The combined effects of elevated FBG and hypocholesterolemia with PLC were analyzed using the Age-scale Cox proportional hazard regression model.
Results
During 1,134,843.68 person*years follow up, a total of 388 PLC cases occured. We found the elevated FBG and hypocholesterolemia increases the risk for PLC, respectively. Compared with the non-hypocholesterolemia/normal FBG group, the risk of PLC was significantly increased in the non-hypocholesterolemia/elevated FBG group (HR=1.19,95%CI 0.88–1.62) and hypocholesterolemia/normal FBG group (HR=1.53,95%CI 1.19–1.97), and in the hypocholesterolemia/elevated FBG group (HR=3.16 95%CI2.13-4.69). And, a significant interaction effect was found of FBG and TC on PLC. All results were independent from the influence of liver disease.
Conclusion
Elevated serum FBG and hypocholesterolemia are risk factors for PLC, especially when combined. Thus, for the prevention and treatment of PLC, serum FBG and TC levels should be investigated.

Keyword

Glucose; Cholesterol; Liver neoplasms; Combined effect; Cohort studies

Figure

  • Fig. 1 Accumulative incidence curves of primary liver cancer in G1–G4 groups.

  • Fig. 2 Influence of the combined effects of serum total cholesterol and fasting blood glucose (FBG) on primary liver cancer by the multivariate Cox proportional hazard model.


Reference

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69–90.
Article
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68:7–30.
Article
3. Zuo T, Zheng R, Zeng H, Zhang S, Chen W. Analysis of liver cancer incidence and trend in China. Zhonghua Zhong Liu Za Zhi. 2015; 37:691–6.
4. Yuen MF, Hou JL, Chutaputti A. Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009; 24:346–53.
Article
5. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018; 3:383–403.
6. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009; 101:1348–55.
Article
7. Han H, Zhang T, Jin Z, Guo H, Wei X, Liu Y, et al. Blood glucose concentration and risk of liver cancer: systematic review and meta-analysis of prospective studies. Oncotarget. 2017; 8:50164–73.
Article
8. Ma C, Gurol ME, Huang Z, Lichtenstein AH, Wang X, Wang Y, et al. Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage: a prospective study. Neurology. 2019; 93:e445–57.
9. Ukawa S, Tamakoshi A, Murakami Y, Kiyohara Y, Yamada M, Nagai M, et al. Pooled analysis of the associations between body mass index, total cholesterol, and liver cancer-related mortality in Japan. Asian Pac J Cancer Prev. 2018; 19:2089–95.
10. Strohmaier S, Edlinger M, Manjer J, Stocks T, Bjorge T, Borena W, et al. Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). PLoS One. 2013; 8:e54242.
Article
11. Kitahara CM, Berrington de Gonzalez A, Freedman ND, Huxley R, Mok Y, Jee SH, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011; 29:1592–8.
Article
12. Iso H, Ikeda A, Inoue M, Sato S, Tsugane S. JPHC Study Group. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer. 2009; 125:2679–86.
Article
13. Nderitu P, Bosco C, Garmo H, Holmberg L, Malmstrom H, Hammar N, et al. The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: a study in the Swedish AMORIS cohort. Int J Cancer. 2017; 141:1148–60.
Article
14. Feng X, Wang G, Li N, Lyu Z, Chen S, Wei L, et al. The association between fasting blood glucose and the risk of primary liver cancer in Chinese males: a population-based prospective study. Br J Cancer. 2017; 117:1405–11.
Article
15. Wang G, Li N, Chang S, Bassig BA, Guo L, Ren J, et al. A prospective follow-up study of the relationship between C-reactive protein and human cancer risk in the Chinese Kailuan Female Cohort. Cancer Epidemiol Biomarkers Prev. 2015; 24:459–65.
Article
16. Shen X, Jin C, Wu Y, Zhang Y, Wang X, Huang W, et al. Prospective study of perceived dietary salt intake and the risk of non-alcoholic fatty liver disease. J Hum Nutr Diet. 2019; 32:802–9.
Article
17. Luo RH, Zhao ZX, Zhou XY, Gao ZL, Yao JL. Risk factors for primary liver carcinoma in Chinese population. World J Gastroenterol. 2005; 11:4431–4.
Article
18. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69:182–236.
19. Kim K, Choi S, Park SM. Association of fasting serum glucose level and type 2 diabetes with hepatocellular carcinoma in men with chronic hepatitis B infection: a large cohort study. Eur J Cancer. 2018; 102:103–13.
Article
20. Joint committee for guideline revision. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018; 15:1–29.
21. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014; 64:485–94.
22. Tanamas SK, Saulnier PJ, Hanson RL, Nelson RG, Hsueh WC, Sievers ML, et al. Serum lipids and mortality in an American Indian population: a longitudinal study. J Diabetes Complications. 2018; 32:18–26.
Article
23. Asano K, Kubo M, Yonemoto K, Doi Y, Ninomiya T, Tanizaki Y, et al. Impact of serum total cholesterol on the incidence of gastric cancer in a population-based prospective study: the Hisayama study. Int J Cancer. 2008; 122:909–14.
Article
24. Yao X, Tian Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. Cancer Causes Control. 2015; 26:257–68.
Article
25. Chrostek L, Supronowicz L, Panasiuk A, Cylwik B, Gruszewska E, Flisiak R. The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins. Clin Exp Med. 2014; 14:417–21.
Article
26. Khalili M, Lombardero M, Chung RT, Terrault NA, Ghany MG, Kim WR, et al. Diabetes and prediabetes in patients with hepatitis B residing in North America. Hepatology. 2015; 62:1364–74.
Article
27. Guo CH, Sun TT, Weng XD, Zhang JC, Chen JX, Deng GJ. The investigation of glucose metabolism and insulin secretion in subjects of chronic hepatitis B with cirrhosis. Int J Clin Exp Pathol. 2015; 8:13381–6.
28. Zhao Y, Xing H. A different perspective for management of diabetes mellitus: controlling viral liver diseases. J Diabetes Res. 2017; 2017:5625371.
Article
29. Papa S, Bubici C, Zazzeroni F, Franzoso G. Mechanisms of liver disease: cross-talk between the NF-kappaB and JNK pathways. Biol Chem. 2009; 390:965–76.
30. Weng CJ, Hsieh YH, Tsai CM, Chu YH, Ueng KC, Liu YF, et al. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol. 2010; 17:1808–15.
Article
31. Adachi Y, Nojima M, Mori M, Matsunaga Y, Akutsu N, Sasaki S, et al. Insulin-like growth factor-related components and the risk of liver cancer in a nested case-control study. Tumour Biol. 2016; 37:15125–32.
Article
32. Wiencke JK. Impact of race/ethnicity on molecular pathways in human cancer. Nat Rev Cancer. 2004; 4:79–84.
Article
33. Muldoon MF, Kritchevsky SB, Evans RW, Kagan VE. Serum total antioxidant activity in relative hypo- and hypercholesterolemia. Free Radic Res. 1996; 25:239–45.
Article
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr